Clinical Trials on Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Total 454 results

Amgen

Completed

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Japan
Pfizer

Withdrawn

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects (SPIRE-ASIA)

Primary Hyperlipidemia or Mixed Dyslipidemia

China
Amgen

Completed

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects (AMG145)

Hypercholesterolemia and High Risk for Cardiovascular Events

Japan
Memorial Sloan Kettering Cancer Center

Completed

Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

High Risk for Postoperative Cardiovascular Events

United States
University of Ioannina

Unknown

Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia

Dyslipidemia

Greece
In His Image
Kos Pharmaceuticals

Completed

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

Dyslipidemia | Hyperlipidemia | Mixed Hyperlipidemia

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy/Tolerability Study (0524A-020)

Primary Hypercholesterolaemia | Mixed Hyperlipidaemia
University Hospital, Montpellier

Not yet recruiting

Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk (COMMEDCARDIO)

Patients at High-Risk of a Cardiovascular Event
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Withdrawn

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors

Cardiovascular Diseases | Hyperlipidemia
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Hyperlipemia

China
Chong Kun Dang Pharmaceutical

Unknown

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Mixed Hyperlipidemia

Korea, Republic of
Cortria Corporation
Montreal Heart Institute

Completed

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Hypertriglyceridemia | Mixed Hyperlipidemia

Canada
Organon and Co

Completed

Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)

Hypercholesterolemia | Hypertriglyceridemia
Organon and Co

Completed

Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)

Hypercholesterolemia | Hypertriglyceridemia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Organon and Co

Completed

A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)

Hypercholesterolemia | Hypertriglyceridemia | Hyperlipidemia
Yale University

Completed

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

High Risk Atherosclerotic Cardiovascular Disease

United States
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204) (REMAINS)

Dyslipidemias | Hypercholesterolemia | Hypertriglyceridemia | High LDL-C | Low HDL-C
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
Sang Hak Lee

Unknown

Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid (AVOCADO)

Mixed Hyperlipidemia

Korea, Republic of
Pfizer

Terminated

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)

Mixed Hyperlipidemia

United States, Canada, Czech Republic, Finland, France, Netherlands
Merck Sharp & Dohme LLC

Completed

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Japan Tobacco Inc.

Completed

Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

Type II Hyperlipidaemia

Netherlands
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Mixed Hyperlipidemia | Non-familial Hypercholesterolemia

China
Novartis

Completed

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Mixed Dyslipidemia | Heterozygous Familial Hypercholesterolemia

Switzerland
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Korea United Pharm. Inc.

Active, not recruiting

Study to Evaluate the Safety and PK of UI018

Hyperlipemia, Mixed

Korea, Republic of
Brigham and Women's Hospital

Active, not recruiting

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management (LDL-ALERT)

ASCVD | Hyperlipemia, Mixed

United States
Akeso

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Hyperlipidemia

China
Pfizer

Completed

Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate

Hyperlipidemia

France
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Akeso

Recruiting

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Hyperlipidemia

China
Akeso

Recruiting

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Hyperlipidemia

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

Dyslipidemia | Hypercholesterolemia | Hyperlipidemia | Hypolipoproteinemia

United States
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia
Sun Yat-sen University

Unknown

The Healthy Cantonese Diet on Cardiometabolic Syndrome

Hyperglycemia | Cardiovascular Diseases | Hypertension | Hyperlipidemias | Cardiovascular Risk Factor | High Blood Pressure
Merck Sharp & Dohme LLC

Completed

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Hyperlipidemia | Hypercholesteremia
Oslo University Hospital
University of Oslo

Completed

Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers

Overweight and Obesity | Type IIb Hyperlipidaemia | Hypercholesterolemia Aggravated

Norway
Nordic Pharma, USA
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Withdrawn

Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction (PrOteCT)

Mixed Hyperlipoproteinemia
Shionogi
Integrium

Completed

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Combined Hyperlipidemia

United States
Institute of Biomedical Chemistry, Russia

Completed

"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia

Combined Hyperlipidemia

Russian Federation
Federal University of Rio Grande do Sul

Completed

Effects of Exercise on Fructose-induced Postprandial Lipemia

Sedentary Lifestyle | Dyslipidemias | Lipid Metabolism Disorders | Carbohydrate Inducible Hyperlipemia
National Institute of Nursing Research (NINR)
Tufts University

Withdrawn

Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels

Arteriosclerosis | Cardiovascular Disease | Hyperlipidemia | Abnormalities
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia

Clinical Trials on Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations